Anna Matton
YOU?
Author Swipe
View article: Enhancing diagnostic precision in Alzheimer's disease: Impact of comorbidities on blood biomarkers for clinical integration
Enhancing diagnostic precision in Alzheimer's disease: Impact of comorbidities on blood biomarkers for clinical integration Open
INTRODUCTION Comorbidities may influence Alzheimer's disease (AD) plasma biomarkers. This study aimed to investigate how medical conditions impact AD plasma biomarkers and whether comorbidity‐adjusted models enhance their diagnostic perfor…
View article: Plasma Proteomic Signatures for Alzheimer's Disease: Comparable Accuracy to <scp>ATN</scp> Biomarkers and Cross‐Platform Validation
Plasma Proteomic Signatures for Alzheimer's Disease: Comparable Accuracy to <span>ATN</span> Biomarkers and Cross‐Platform Validation Open
Background There is growing recognition of the potential of plasma proteomics for Alzheimer's Disease (AD) risk assessment and disease characterization. However, differences between proteomics platforms introduce uncertainties regarding cr…
View article: Commonly prescribed multi‐medication therapies exert sex‐specific effects on Alzheimer's disease pathology and metabolomic profiles in <i>App<sup>NL‐G‐F</sup></i> mice: Implications for personalized therapeutics in aging
Commonly prescribed multi‐medication therapies exert sex‐specific effects on Alzheimer's disease pathology and metabolomic profiles in <i>App<sup>NL‐G‐F</sup></i> mice: Implications for personalized therapeutics in aging Open
INTRODUCTION Polypharmacy is common among older adults and people with dementia. Multi‐medication therapy poses risks of harm but also targets comorbidities and risk factors associated with dementia, offering therapeutic potential. METHODS…
View article: Cell-type specific profiling of human entorhinal cortex at the onset of Alzheimer’s disease neuropathology
Cell-type specific profiling of human entorhinal cortex at the onset of Alzheimer’s disease neuropathology Open
Neurons located in layer II of the entorhinal cortex (ECII) are the primary site of pathological tau accumulation and neurodegeneration at preclinical stages of Alzheimer’s disease (AD). Exploring the alterations that underlie the early de…
View article: Biological signatures in the Alzheimer’s continuum discriminate between diagnosis-related and -unrelated associations to ATN categories
Biological signatures in the Alzheimer’s continuum discriminate between diagnosis-related and -unrelated associations to ATN categories Open
Alzheimer’s disease and related dementias have a multifactorial aetiology and heterogeneous biology. The current study aims to identify different biological signatures in a deeply phenotyped memory clinic patient population. In this cross-…
View article: Brain MRI volumetry and atrophy rating scales as predictors of amyloid status and eligibility for anti-amyloid treatment in a real-world memory clinic setting
Brain MRI volumetry and atrophy rating scales as predictors of amyloid status and eligibility for anti-amyloid treatment in a real-world memory clinic setting Open
Predicting amyloid status is crucial in light of upcoming disease-modifying therapies and the need to identify treatment-eligible patients with Alzheimer’s disease. In our study, we aimed to predict CSF-amyloid status and eligibility for a…
View article: Understanding the variability in plasma biomarker levels in the context of established biomarkers of Alzheimer’s disease
Understanding the variability in plasma biomarker levels in the context of established biomarkers of Alzheimer’s disease Open
Background Plasma biomarkers are on the verge of being introduced as screening tools for detecting Alzheimer's disease (AD). Yet, previous studies yielded contradictory results regarding the extent to which distinct plasma biomarkers refle…
View article: The World‐Wide FINGERS Global Strategy for Precision Prevention of Dementia and Alzheimer’s Disease
The World‐Wide FINGERS Global Strategy for Precision Prevention of Dementia and Alzheimer’s Disease Open
Background Precision Prevention –the right intervention for the right person at the right time– is a recent endeavour in the Alzheimer’s disease (AD) field, requiring the integration of multidimensional data from large, representative popu…
View article: Associations between neuropsychological tests, plasma biomarkers and PET amyloid scans in a memory clinic cohort
Associations between neuropsychological tests, plasma biomarkers and PET amyloid scans in a memory clinic cohort Open
Background Studies on plasma biomarkers have shown promising results for Alzheimer’s disease(AD) neuropathology in a research setting, but their associations to neuropsychological(NP) tests have not been extensively studied in clinical coh…
View article: New proteomic signatures in Alzheimer Disease identification and Mild Cognitive Impairment Classification
New proteomic signatures in Alzheimer Disease identification and Mild Cognitive Impairment Classification Open
Background Emerging technologies and novel biomarker tools are transforming the field of Alzheimer’s disease, allowing for a more in‐depth exploration of biological mechanisms underpinning the disease aetio‐pathogenesis. In this context, t…
View article: Brain amyloid load, subjective memory complaints, and cognitive trajectories in older individuals at risk for dementia
Brain amyloid load, subjective memory complaints, and cognitive trajectories in older individuals at risk for dementia Open
Background and Purpose This study evaluated associations of brain amyloid with 2‐year objective and subjective cognitive measures in a trial‐ready older general population at risk for dementia. Methods Forty‐eight participants in the Finni…
View article: Assessment of brain‐derived extracellular vesicle enrichment for blood biomarker analysis in age‐related neurodegenerative diseases: An international overview
Assessment of brain‐derived extracellular vesicle enrichment for blood biomarker analysis in age‐related neurodegenerative diseases: An international overview Open
INTRODUCTION Brain‐derived extracellular vesicles (BEVs) in blood allows for minimally‐invasive investigations of central nervous system (CNS) ‐specific markers of age‐related neurodegenerative diseases (NDDs). Polymer‐based EV‐ and immuno…
View article: DEAD Box Helicase 24 Is Increased in the Brain in Alzheimer’s Disease and AppN-LF Mice and Influences Presymptomatic Pathology
DEAD Box Helicase 24 Is Increased in the Brain in Alzheimer’s Disease and AppN-LF Mice and Influences Presymptomatic Pathology Open
At the time of diagnosis, Alzheimer’s disease (AD) patients already suffer from significant neuronal loss. The identification of proteins that influence disease progression before the onset of symptoms is thus an essential part of the deve…
View article: CYP46A1-mediated cholesterol turnover induces sex-specific changes in cognition and counteracts memory loss in ovariectomized mice
CYP46A1-mediated cholesterol turnover induces sex-specific changes in cognition and counteracts memory loss in ovariectomized mice Open
The brain-specific enzyme CYP46A1 controls cholesterol turnover by converting cholesterol into 24 S -hydroxycholesterol (24OH). Dysregulation of brain cholesterol turnover and reduced CYP46A1 levels are observed in Alzheimer’s disease (AD)…
View article: Prevention of Alzheimer’s by a Multimodal Lifestyle Protocol – Working‐mechanisms for Memory Gains: Mouse‐PAW
Prevention of Alzheimer’s by a Multimodal Lifestyle Protocol – Working‐mechanisms for Memory Gains: Mouse‐PAW Open
Background The approach of changing multiple lifestyle factors simultaneously targeting different risk factors is expected to have the greatest potential in preventing or delaying the progression of dementia. Nevertheless, it is largely un…
View article: Blood biomarkers of Alzheimer’s disease as predictors of eligibility for disease‐modifying treatment
Blood biomarkers of Alzheimer’s disease as predictors of eligibility for disease‐modifying treatment Open
Background Blood biomarkers show promise in screening for Alzheimer’s disease (AD) brain pathology, but best predictors of eligibility for disease‐modifying treatment remain unclear. We have previously reported estimates for potential elig…
View article: Associations between Aβ‐PET, CSF pTau, and plasma GFAP, pTau181, pTau231 in memory clinic patients
Associations between Aβ‐PET, CSF pTau, and plasma GFAP, pTau181, pTau231 in memory clinic patients Open
Background Previous studies yielded contradictory findings regarding the association of plasma biomarkers with established biomarkers of tau and amyloid (Aβ) pathology. Here, we aim to examine the relationship between Aβ‐PET and CSF pTau w…
View article: Diurnal cortisol, neuroinflammation, and neuroimaging visual rating scales in memory clinic patients
Diurnal cortisol, neuroinflammation, and neuroimaging visual rating scales in memory clinic patients Open
Background Neuroinflammation is considered a hallmark of the Alzheimer’s disease (AD) pathogenic process. Dysregulations in stress hormones (cortisol) may increase AD risk and are related to brain atrophy. This cross‐sectional study aims t…
View article: Alzheimer’s disease biomarker profiling in a memory clinic cohort without common comorbidities
Alzheimer’s disease biomarker profiling in a memory clinic cohort without common comorbidities Open
Background Comorbidities such as hypertension, hypercholesterolemia and diabetes are known contributors to Alzheimer disease (AD) progression. However, their mechanistic contribution to pathology and neurodegeneration has not been clarifie…
View article: Diurnal cortisol, neuroinflammation and cerebrovascular dysfunction biomarkers in a memory clinic cohort: findings from the Co-STAR study
Diurnal cortisol, neuroinflammation and cerebrovascular dysfunction biomarkers in a memory clinic cohort: findings from the Co-STAR study Open
Cortisol dysregulation, neuroinflammation and cerebrovascular dysfunction are biological processes that have been separately shown to be affected in Alzheimer’s disease (AD). Here, we aimed to identify biomarker signatures reflecting these…
View article: Multimodal Precision Prevention - A New Direction in Alzheimer's Disease
Multimodal Precision Prevention - A New Direction in Alzheimer's Disease Open
At least 40% of all dementia has been linked to modifiable risk factors suggesting a clear potential for preventative approaches targeting these factors. Despite the recent promising findings from anti-amyloid monoclonal antibodies, a limi…
View article: Assessment of brain-derived extracellular vesicle enrichment for blood biomarker analysis in age-related neurodegenerative diseases: An international overview
Assessment of brain-derived extracellular vesicle enrichment for blood biomarker analysis in age-related neurodegenerative diseases: An international overview Open
INTRODUCTION Brain-derived extracellular vesicles (BEVs) in blood allows for minimally- invasive investigations of CNS-specific markers of age-related neurodegenerative diseases (NDDs). Polymer-based EV- and immunoprecipitation (IP)-based …
View article: APOE-Genotype and Insulin Modulate Estimated Effect of Dietary Macronutrients on Cognitive Performance: Panel Analyses in Nondiabetic Older Adults at Risk of Dementia
APOE-Genotype and Insulin Modulate Estimated Effect of Dietary Macronutrients on Cognitive Performance: Panel Analyses in Nondiabetic Older Adults at Risk of Dementia Open
APOE-based precision nutrition appears conceptually promising, but replications in wider samples are warranted, as well as support from trials. Both relative hyper- and hypoinsulinemia might modulate the effect of diet on cognition.